Strategic Funding The organization actively funds SCN8A and related PCDH19 research, indicating potential opportunities for partnerships with grant programs, research collaborations, and sponsor-backed clinical studies.

Leadership Transition Recent appointment of Danielle Hayward as Interim Executive Director suggests openness to new partnerships and refreshed outreach strategies; leverage this period to establish introductory conversations with governance.

Community Engagement Longstanding annual Clinician, Researcher, and Family gatherings aligned with major epilepsy conferences demonstrate strong community networks; potential for sponsorships, exhibit opportunities, and data-sharing collaborations.

Digital & Tech Tech stack includes PayPal, AfterPay, and regulatory-grade data initiatives via Ciitizen partnerships; indicates readiness for donor management solutions, patient consented data workflows, and scalable fundraising platforms.

Financial Scale Revenue under $1M with collaborative history across epilepsy and rare disease groups; target mid-size grantmakers, corporate sponsors, and technology partners seeking impact in SCN8A and rare disease research.